Biocon seeking rich partner for insulin pill development

Diabetes patients currently inject their insulin, of course. But India's Biocon sees opportunity in developing an oral insulin pill, despite a late-stage clinical trial setback this year for its IN-105 oral insulin treatment. Biocon is in advance discussions with potential partners to continue the pill's development, Reuters is reporting, with potential tweaks in design of the trial protocol. Rumored potential partners include Novo Nordisk ($NVO) and Eli Lilly ($LLY). Story

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.